We use cookies to improve your experience on this site. By viewing our pages, you give us consent to use cookies. Find out more.

Don’t invest unless you’re prepared to lose all the money you invest. NextFin promotes high - risk investments and you are unlikely to be protected if something goes wrong.
Take 2 minutes to learn more.

Equity Crowdfunding Pitches

Showing results
Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go: Extended investment: Withheld
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go: TBC investment: £127,001
PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go: Extended investment: £295,000
Docandu is an innovative digital health platform designed both for patients & doctors, making digital healthcare accessible from anywhere. Docandu aims to be a key tech health service provider, starting from Greece, improving the existing national and private health care services. The global digital health market is estimated to be worth $536 Billion by 2025. To date, they have developed two separate apps for doctors and patients. They have also received an angel investment of 100,000 Euros and sponsorship of $25,000 from Microsoft. The company has initiated early-stage relationships with a couple of Greek public and private health entities. With the proceeds, they will execute their go-to-market strategy and make global health ID a reality, by expanding its affiliate network of doctors, health providers and public health systems.

Pitch Rated

82%

Gold

rating powered by

CROWD RATING™

days to go: Expired investment: £70,900
miiCARE is a MedTech specialising in AI applied to geriatrics (elderly care). Its key product miiCUBE offers cutting-edge home-based and customised healthcare, helping the elderly enjoy their independence while being comprehensively connected to their families, friends, and neighbours. The company aims to provide these benefits to one billion people by 2028, comprising older people, family members and carers. Till date, miiCARE has secured partnerships with the UK’s largest NHS trust, Ebbsfleet Garden City, O2, Bristol Careline and Microsoft, and won multiple social impacts and digital health awards during the last 12 months. Funds raised will be used mainly for fulfilling pre-orders and close interests for large contracts with corporates, marketing and logistics, product development, sales and salaries.

Pitch Rated

84%

Gold

rating powered by

CROWD RATING™

days to go: Expired investment: £103,672
DNApal is a personalised diet, health and fitness app that combines DNA infomation with other factors like age, weight, diet, family history and health goals. Two of the largest consumer DNA companies, 23andMe and Ancestry.com, have tested over 18m people. DNApal is capable of interpreting DNA results from these companies to provide precise recommendations on how to improve diet, hormone balance, weight loss, sleep, fitness & more. The company also won the best pitch at VentureFest 2019 at Oxford Brookes University. DNApal is aiming to launch MVP in January 2020 (iOS). The company is also aiming to recommend further testing and specific supplements where necessary and offer 1:1 consultations with a specialist. With the fund raised, DNApal plans to develop the full scope of the app, weekly goals, content challenges to keep users committed.

Pitch Rated

70%

Overall

rating powered by

CROWD RATING™

days to go: Expired investment: £49,990
Forth allows users to track their wellbeing to see what impact their lifestyle is having on their health. It allows users to maximise their performance during athletics, keep track of their inner health and focus on things they may need to work on for greater overall wellbeing. 
days to go: Expired investment: £165,760
Medics2You's is a hybrid telehealth platform that connects patients with healthcare experts around the globe with focus on Africa through a smart device from anywhere, six days a week. The company has a pilot project underway in Nigeria, a nation which spends $500m-1bn annually on outbound healthcare tourism. Medics2You aims to reach out to over 100m people unable to access quality healthcare. Medics2You's partnership with Lantum has given the company access to 18000+ doctors and 3000 clinicians. The funds will be used to create the web portal, expand the team, set up local centres, and enhance marketing activities.

Pitch Rated

76%

Gold

rating powered by

CROWD RATING™

days to go: Expired investment: £156,370
Personalised Protein Co (PPCo) is a direct-to-consumer supplement brand that bridges the gap between technology and fitness. Leveraging on the growing UK vitamin and supplement industry, which is worth over £800m, PPCo offers expert guidance, bespoke product, clear pricing, and consumer-friendly subscription service. More than 9,000 people have signed up for the company's pre-registered launch campaign providing it 1,200 customers and 5000+ Instagram followers. With the proceeds, the company will improve its technology, automation, and aim at acquiring new customers. PPCo is raising money to invest in its product and scale its marketing efforts.
days to go: Expired investment: £192,770
Elite Training Experience (ETE) aims to become the de facto provider of warm weather triathlon training camps, not just to the UK's 140,000 triathletes but to the estimated 2,000,000 triathletes around the world.
days to go: Expired investment: £139,470
  • Internet Business Awards Category Award Winner 2015
  • Hertfordshire Business Awards Finalist 2014

As seen in:

  • The Guardian
  • Financial Times
  • Yahoo! Finance
  • The Times
  • The Daily Telegraph